Purple Biotech (PPBT) Income from Continuing Operations (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Income from Continuing Operations of 2200000.0 for Q1 2026, up 67.05% year-over-year from 1317000.0 in Q1 2025, and down 90.5% quarter-over-quarter from 23153000.0 in Q4 2025.
Purple Biotech (PPBT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Income from Continuing Operations for 13 consecutive years, with 2200000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 67.05% year-over-year to 2200000.0; the TTM figure through Mar 2026 stood at 27730000.0 (up 310.75% YoY), while the FY2025 annual figure was 26492000.0, down 263.0% from the prior year.
- Income from Continuing Operations eased to 2200000.0 in Q1 2026 per PPBT's latest filing, from 23153000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 23153000.0 in Q4 2025 and bottomed at 629000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 4575588.24 across 5 years, with a median of 3450000.0 in 2022.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 77.29% — and 2025, when it jumped 3580.92%.
- Purple Biotech's Income from Continuing Operations stood at 6007000.0 in 2022, then plunged by 53.89% to 2770000.0 in 2023, then slumped by 77.29% to 629000.0 in 2024, then surged by 3580.92% to 23153000.0 in 2025, then sank by 90.5% to 2200000.0 in 2026.
- Business Quant data shows PPBT's Income from Continuing Operations at 2200000.0 in Q1 2026, 23153000.0 in Q4 2025, and 1239000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | 1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 23.15 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 629,000.00 |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | 5.02 Mn |
| Jun 30, 2023 | 4.86 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | 6.01 Mn |
| Sep 30, 2022 | 4.82 Mn |
| Jun 30, 2022 | 3.45 Mn |
| Mar 31, 2022 | 7.23 Mn |
| Dec 31, 2021 | 7.57 Mn |
| Sep 30, 2021 | 2.95 Mn |
| Jun 30, 2021 | 3.44 Mn |